Caris Life Sciences, a cancer diagnostics and treatment biotech, raised $494 million in its IPO at $21 per share, above its previously planned $19 to $20 per share range.
By the numbers: The offering values Caris at about $5.95 billion, based on outstanding shares, lower than its 2021 valuation of $7.83 billion.
